Zachary Hunter
Pre-Doctoral Trainee
Boston University School of Medicine, Division of Graduate Medical Sciences
Dept of Pathology & Laboratory Medicine

Waldenström's macroglobulinemia
Whole Genome Sequencing
Lymphoma Predisposition
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Gustine JN, Meid K, Dubeau T, Severns P, Hunter ZR, Guang Y, Xu L, Treon SP, Castillo JJ. Ibrutinib discontinuation in Waldenström macroglobulinemia: etiologies, outcomes, and IgM rebound. Am J Hematol. 2017 Dec 27. PMID: 29280186.
  2. Castillo JJ, Gustine JN, Meid K, Xu L, Hunter ZR, Treon SP. Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom''s macroglobulinemia. Am J Hematol. 2017 Dec 08. PMID: 29218718.
  3. Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, Meid K, Guerrera ML, Munshi M, Chan G, Chen J, Kofides A, Patterson CJ, Yang G, Liu X, Severns P, Dubeau T, Hunter ZR, Castillo JJ. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2017 Nov 27. PMID: 29181840.
  4. Vos JM, Tsakmaklis N, Patterson CJ, Meid K, Castillo JJ, Brodsky P, Ganz T, Pals ST, Kersten MJ, Xu L, Yang G, Treon SP, Hunter ZR. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica. 2017 Nov; 102(11):e452-e455. PMID: 28798070.
  5. Castillo JJ, Hunter ZR, Yang G, Treon SP. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. Expert Rev Hematol. 2017 Aug; 10(8):739-744. PMID: 28617062.
  6. Gustine JN, Meid K, Dubeau T, Hunter ZR, Xu L, Yang G, Ghobrial IM, Treon SP, Castillo JJ. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017 Jun; 177(5):717-725. PMID: 28485115.
  7. Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, Kofides A, Patterson CJ, Meid K, Gustine J, Dubeau T, Palomba ML, Advani R, Castillo JJ, Furman RR, Hunter ZR, Treon SP. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017 May 04; 129(18):2519-2525. PMID: 28235842; DOI: 10.1182/blood-2017-01-761726;.
  8. Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001. PMID: 28294689; DOI: 10.1200/JCO.2016.71.0814;.
  9. Treon SP, Meid K, Tripsas C, Heffner LT, Eradat H, Badros AZ, Xu L, Hunter ZR, Yang G, Patterson CJ, Gustine J, Castillo JJ, Matous J, Ghobrial IM. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404. PMID: 27836860; DOI: 10.1158/1078-0432.CCR-16-1918;.
  10. Gustine JN, Meid K, Hunter ZR, Xu L, Treon SP, Castillo JJ. MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. Br J Haematol. 2016 Oct 17. PMID: 27748515; DOI: 10.1111/bjh.14386;.
Showing 10 of 96 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 96 publications over 13 distinct years, with a maximum of 13 publications in 2016

Contact for Mentoring:

Hunter's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department